Back to catalogue
№ 032 26 filings · 2021-08-24 → 2026-08-21

ACTIVEOPS PLC

AOM
Technology Share price 192p Market cap £138m Overall fit 665 /1000

Fits AI-receiver (vertical SaaS + proprietary data + AI upgrade cycle), operating leverage (90% SaaS GM, path from 9% to 25% EBITDA) and fair valuation (2.8x EV/ARR with £30m net cash). Held back from top band by narrow moat and short track record on the AI-driven NRR acceleration.

Fair value range 220p–285p Mid case · £179m
Absolute upside +30.1% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • 5-year track record of meet-or-beat guidance
  • Clean SaaS KPI disclosure (ARR, NRR, organic split)
  • 90% SaaS gross margin makes valuation methodology unambiguous
Limits the call
  • Enlighten integration only 6-9 months in with a lost customer already
  • AI-driven NRR uplift only ~2 years old — durability unproven
Methodology

EV/ARR multiple with EV/Sales and forward EBITDA cross-check

In one line · bull case

Re-accelerating vertical SaaS with genuine AI-driven upgrade economics, 90% SaaS gross margins and a debt-free balance sheet, trading at an undemanding ~2.8x EV/ARR.

In one line · biggest risk

Enlighten integration delivering weaker synergies or further customer losses would undermine both management credibility and the FY27 margin-expansion story.

Drivers
AI beneficiary 72 /100
AI features drive Series 3/4/5 upgrades and NRR expansion to 119%; 15-year proprietary operational dataset is a training-data moat.
Operating leverage 78 /100
90% SaaS gross margin, largely fixed cost base, management targeting 25% EBITDA at £100m ARR from 9% today.
Earnings vs expectations 72 /100
Multiple beats (FY23, FY24, FY26) and FY25 in line; FY26 revenue and EBITDA both beat consensus.
Growth momentum 82 /100
Organic revenue growth accelerating from 5% (FY24) to 14% (FY25) to 28% (FY26); NRR up sharply.
Moat 55 /100
Narrow but real — proprietary operational dataset, embedded AOM methodology, enterprise switching costs.
Earnings quality 60 /100
Adjusted EBITDA reconciles clearly but Enlighten M&A costs and capitalised R&D create some noise; H1 statutory loss.
Management quality 65 /100
Consistent delivery vs stated targets and sensible capital allocation; Enlighten customer loss is a minor red flag.
Cyclicality 35 /100
Recurring SaaS with sticky enterprise contracts and 119% NRR; some cyclicality via BPO/banking cost cycles.
Leverage 10 /100
Debt-free with ~£30m gross cash post trademark disposal; fortress balance sheet.
Value-trap signals · 3
  • Enlighten customer termination and £3.5m deferred consideration cut
  • Significant goodwill/intangibles (£25m) vs modest net assets (£9m) — impairment risk
  • AIM small-cap illiquidity limits institutional participation

ActiveOps PLC (AOM) — Investment Research Note

Executive summary

ActiveOps is a UK-listed vertical SaaS provider selling "Decision Intelligence" software — workforce planning, capacity management and case tracking — into large banking, insurance, healthcare and BPO back-office operations, augmented by AI features drawn from 15+ years of proprietary operational data. The trajectory has inflected sharply in FY26: organic revenue growth accelerated to 28% (vs 14% FY25 and 5% FY24), NRR jumped to 119% (from 106%), and Adjusted EBITDA nearly doubled to £4.2m on £45m revenue after absorbing the Enlighten acquisition 2026-04-21 FY26 trading update. The most important valuation point today is that a re-accelerating, 90%-SaaS-gross-margin business with £23.6m net cash and a credible path to £100m ARR / 25% EBITDA margin is trading at ~2.8x EV/ARR — undemanding for the growth on offer, though execution risk on Enlighten and AIM illiquidity temper conviction.

Fair value estimate

Range: 220p – 285p per share (implied market cap ~£157m – £204m); midpoint ~250p / £179m.

Methodology: primarily EV/ARR multiple triangulated against EV/Sales and a rough forward EBITDA cross-check.

Key assumptions:

  • FY27E organic ARR growth ~20% + Enlighten contribution → exit ARR ~£48–50m
  • Net cash of ~£30m post trademark disposal (£23.6m cash + £7.4m WorkiQ trademark proceeds, before Enlighten deferred payments of ~£5.8m + ~£0.2m reduced) 2026-04-21
  • Applied 2.8x–3.5x EV/ARR — light end of UK SaaS peers, reflecting AIM discount, BPO customer mix, and integration risk
  • Cross-check: FY27E revenue ~£52m at 3.0x EV/Sales = £156m EV + £30m cash = £186m equity (~260p); FY27E EBITDA ~£7–9m as Enlighten synergies land at 20x = £140–180m EV
  • Bull scenario (£100m ARR, 25% EBITDA at ~5 years out, 15x EV/EBITDA discounted at 10%): supports upper end

Vs current £148.3m market cap: midpoint 250p implies ~24% upside; range spans +10% to +42%.

Sector context

  • Sector: Technology (vertical enterprise SaaS). Confirmed.
  • Profile vs peers: Above typical peers on gross margin (SaaS 90%, blended 84%) and balance-sheet quality (debt-free, £30m net cash). Growth is now above peers post-acceleration. Scale is well below (£45m revenue). Operating margin (9% EBITDA) is below scaled SaaS peers, reflecting deliberate sales investment.
  • Listed peers (approximate): Cerillion (billing SaaS for telcos), Kainos (public sector/Workday consulting + SaaS), Alfa Financial Software (asset finance SaaS), GB Group (identity SaaS) — all UK-listed enterprise SaaS with recurring-revenue models.

Investment thesis

  1. Organic growth has visibly inflected as AI features drive both new-logo wins and upgrade/expansion — a demonstrable AI-receiver dynamic, not marketing. Organic ARR growth rose to 25% (FY25: 13%), NRR to 119% (FY25: 106%), with 53% of ControliQ ARR now on Series 3 and 14% on Series 4 (Series 5 in beta) 2026-04-21 FY26 update. Customers upgrade specifically to access AI features (Smart Planning, Opi coach, Executive Insights) — value-per-seat rises when AI is embedded, exactly the vertical-SaaS-plus-AI pattern that captures AI budgets.
  2. Fortress balance sheet + genuine operating leverage funds the plan without dilution risk. £23.6m period-end cash plus $10m (£7.4m) received post-period from the WorkiQ trademark sale gives ~£30m gross cash against zero debt 2026-04-21. SaaS gross margin is 90% and central costs are largely fixed; management explicitly targets 25% EBITDA margin at £100m ARR — implying incremental EBITDA margin of ~30%+ on additional revenue 2025-11-04 Capital Markets Day.
  3. Valuation does not require the bull case. At ~£117m EV / £41.5m ARR = 2.8x, the shares are priced modestly for a SaaS business now growing organic ARR at 25% with expanding NRR. Even flat multiples with mid-teens ARR growth deliver total returns; multiple expansion toward scaled-SaaS norms provides optionality 2025-11-27 interim results.

Key risks

  1. Enlighten integration risk and questionable deal quality. Post-period a customer notified intention to terminate, reducing FY27/28 ARR contribution and cutting deferred consideration by ~£3.5m 2026-04-21. £11m of goodwill and £8m of intangibles sit on the balance sheet; a further customer loss could trigger impairment and dent management credibility.
  2. BPO/banking customer concentration and sales-cycle elongation. Customers are large regulated enterprises (Nationwide, TD Bank, Elevance, Xchanging); management has repeatedly referenced "elongated enterprise sales cycles" through FY24-FY25 2024-04-24 and 2024-11-14. A recessionary pullback in bank cost programmes could stall the growth reacceleration.
  3. AIM small-cap illiquidity and thin operating profit base. £4.2m Adjusted EBITDA (9% margin) is small; a modest cost overrun, adverse FX, or a slower-than-planned Enlighten synergy delivery could see EBITDA disappoint despite topline growth. The stock has traded in a 166p–286p range over the past year — inferred from market data.

Operating leverage

This is a textbook operating-leverage story. SaaS gross margin is 90% and blended gross margin is 84% — every incremental £1 of SaaS revenue carries near-90p contribution 2025-11-27 interim. Fixed costs (product/R&D at £2.9m H1, most of Sales & Marketing, central G&A) do not scale linearly with revenue. Management's own bridge — from FY26 £45m revenue / 9% EBITDA margin to a medium-term £100m ARR / 25% EBITDA — implies incremental revenue drops through at roughly 30%+ EBITDA margin. Applying this to an upside scenario: a 15% revenue beat over consensus (~£7m) would plausibly add £2m+ to EBITDA, i.e. ~50% of the FY26 base. The observable inflection is the SaaS gross margin trending up (90% H1 FY26 vs 88% H1 FY25) and NRR accelerating without proportionate cost increase. The main leverage constraint is the current sales-investment cycle: management is deliberately reinvesting to hire ~six senior enterprise sellers and partner leadership, which suppresses near-term operating margin but should unlock it in FY27-FY28 2025-11-27.

Value-trap signals

  • Enlighten customer termination and consideration cut suggest inherited customer quality is weaker than modelled — worth watching but not a value-trap flag in isolation.
  • Meaningful goodwill/intangibles (£25m intangibles vs £9m net assets) create impairment risk.
  • H1 FY26 statutory loss (£0.7m) despite adjusted profit, driven by £1.4m M&A costs — one-off but reduces reported earnings quality this year.
  • No dividend; capital is being retained for growth (acceptable for this stage).
  • Otherwise, no classic value-trap markers: no debt, no revenue decline, no repeated guidance misses, no related-party issues, no terminal-decline sector.

Earnings vs expectations

The pattern across the filings is consistently meet-to-beat:

  • FY23: ahead of consensus (£25m vs £24.6–25.1m; EBITDA positive vs (£0.5m) expected) 2023-04-25.
  • FY24: ahead of consensus (£26.8m vs £27.3-27.4m on revenue — slightly light; EBITDA £2.2m+ vs £1.0–1.3m — well ahead; cash ahead) 2024-04-24.
  • FY25: in line with expectations, EBITDA flat as planned sales investment absorbed leverage 2025-04-24.
  • H1 FY26: October 2025 trading update signalled full year "comfortably ahead" of consensus; November interims delivered 2025-10-15, 2025-11-27.
  • FY26: revenue £45m vs consensus £43m and EBITDA £4.2m vs £3.9m — beat on both 2026-04-21.

Summary: five consecutive years of meeting or beating guidance, with FY26 the most material beat and clear evidence of upside surprise on organic momentum.

Conviction

Rating: 3.5/5 (rounded to 4).

Anchoring factors: (i) high-quality, well-disclosed SaaS financials with consistent KPIs (ARR, NRR, organic split); (ii) five-year track record of meet-or-beat delivery; (iii) methodology (EV/ARR + EV/EBITDA cross-check) is unambiguous for a SaaS business with 90% gross margin. Limiting factors: (i) Enlighten integration is only 6-9 months in, and one lost customer already suggests inherited quality is soft; (ii) the AI-driven upgrade cycle (Series 3→4→5) is only ~2 years old — durability of the NRR uplift needs another 12-18 months of proof; (iii) small AIM float creates de-rating risk if sentiment turns.

Driver scoring rationale (0-100)

  • ai_beneficiary (72): Legitimate vertical-SaaS AI beneficiary — customers pay materially more per seat to upgrade to AI-enhanced Series 3/4/5; proprietary 15+ year operational dataset is a training-data moat; NRR acceleration to 119% is direct evidence.
  • operating_leverage (78): 90% SaaS gross margin, largely fixed cost base, explicit management path from 9% to 25% EBITDA margin at ~2.4x current revenue.
  • earnings_surprise_trend (72): Multiple beats in FY23, FY24, FY26; FY25 in line; no misses in the sample.
  • cyclicality (35): SaaS recurring revenue, high NRR, sticky enterprise contracts. Some cyclicality via BPO/banking cost cycles but not deeply cyclical.
  • moat (55): 15-year proprietary dataset + operational methodology (AOM) + enterprise switching costs. Not a monopoly; competitors exist (Enlighten was one). Rated as narrow-but-real.
  • leverage (10): Debt-free with £30m gross cash post trademark sale; fortress balance sheet.
  • earnings_quality (60): Adjusted EBITDA is used but reconciles clearly; SaaS revenue recognition is standard; some noise from Enlighten M&A costs, contingent consideration and capitalised R&D (£1.0m H1 FY26); statutory loss due to M&A costs.
  • management_quality (65): Delivered on consecutive years of stated targets, sensible capital allocation (debt-free acquisition, trademark monetisation). Enlighten deal quality concern is a minor red flag.
  • growth_momentum (82): Organic revenue growth accelerated from 5% (FY24) to 14% (FY25) to 28% (FY26); ARR growth 25% organic; NRR expanding — clear acceleration.

Overall score: 665 / 1000

Sits in the "strong buy with one or two reservations" band. Fits three of the four investor pillars: (i) genuine AI-receiver via vertical SaaS upgrade economics; (ii) high operating leverage with quantified path to margin expansion; (iii) fair valuation with a strong balance sheet providing downside protection. The one reservation is that the moat is narrow (execution-led) and the AI-driven acceleration is early — one more year of NRR data would materially raise conviction and score.

Filings consulted · 31

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-21Posting OF Annual Report And Notice OF Agm2026-08-21_9734409_posting-of-annual-report-and-notice-of-agm.md0.95
  2. 2026-04-21Full Year Trading Update And Notice OF Results2026-04-21_9529261_full-year-trading-update-and-notice-of-results.md0.85
  3. 2025-11-27Interim Results2025-11-27_9259946_interim-results.md0.77
  4. 2025-11-04Capital Markets Day2025-11-04_9210202_capital-markets-day.md0.81
  5. 2025-10-15H1 2026 Trading Update And Notice OF Results2025-10-15_9171327_h1-2026-trading-update-and-notice-of-results.md0.72
  6. 2025-09-29Result OF Agm2025-09-29_9138040_result-of-agm.md0.26
  7. 2025-09-04Notice OF Agm2025-09-04_9087993_notice-of-agm.md0.26
  8. 2025-04-24Full Year Trading Update And Notice OF Results2025-04-24_8843102_full-year-trading-update-and-notice-of-results.md0.55
  9. 2024-11-14Interim Results2024-11-14_8548917_interim-results.md0.58
  10. 2024-11-11Notice OF Analyst And Investor Presentations2024-11-11_8541003_notice-of-analyst-and-investor-presentations.md0.46
  11. 2024-10-17Trading Update And Notice OF Half Year Results2024-10-17_8491049_trading-update-and-notice-of-half-year-results.md0.58
  12. 2024-09-26Result OF Agm And Confirmation OF Board Changes2024-09-26_8442390_result-of-agm-and-confirmation-of-board-changes.md0.20
  13. 2024-08-22Notice OF Agm2024-08-22_8380355_notice-of-agm.md0.14
  14. 2024-04-24Full Year Trading Update And Notice OF Results2024-04-24_8153197_full-year-trading-update-and-notice-of-results.md0.38
  15. 2023-11-14Interim Results2023-11-14_7878863_interim-results.md0.41
  16. 2023-11-10Notice OF Investor Presentation2023-11-10_7872750_notice-of-investor-presentation.md0.32
  17. 2023-10-18Trading Update And Notice OF Half Year Results2023-10-18_7822972_trading-update-and-notice-of-half-year-results.md0.41
  18. 2023-09-28Result OF Agm2023-09-28_7784263_result-of-agm.md0.14
  19. 2023-08-23Publication OF Annual Report And Notice OF Agm2023-08-23_7713737_publication-of-annual-report-and-notice-of-agm.md0.24
  20. 2023-06-26Notice OF Results And Investor Presentation2023-06-26_7593726_notice-of-results-and-investor-presentation.md0.17
  21. 2023-04-25Full Year Trading Update2023-04-25_2974_full-year-trading-update.md0.21
  22. 2023-04-25Full Year Trading Update2023-04-25_7496993_full-year-trading-update.md0.21
  23. 2022-11-29Interim Results2022-11-29_7218864_interim-results.md0.23
  24. 2022-10-25Trading Update And Notice OF Half Year Results2022-10-25_7156742_trading-update-and-notice-of-half-year-results.md0.23
  25. 2022-09-29Result OF Agm2022-09-29_7170749_result-of-agm.md0.07
  26. 2022-08-08Publication OF Annual Report And Notice OF Agm2022-08-08_7012736_publication-of-annual-report-and-notice-of-agm.md0.24
  27. 2022-03-24Trading Update2022-03-24_7049839_trading-update.md0.21
  28. 2021-11-25Interim Results2021-11-25_6591321_interim-results.md0.23
  29. 2021-10-20Trading Update And Notice OF Results2021-10-20_6859957_trading-update-and-notice-of-results.md0.21
  30. 2021-09-30Result OF Agm2021-09-30_6645415_result-of-agm.md0.07
  31. 2021-08-24Publication OF Annual Report And Notice OF Agm2021-08-24_6634767_publication-of-annual-report-and-notice-of-agm.md0.24

This research note was authored by a large language model after reading 26 regulatory filings published between 2021-08-24 and 2026-08-21. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.